Leerink Partners Downgrades CVS Health (CVS) to Market Perform

Go back to Leerink Partners Downgrades CVS Health (CVS) to Market Perform

CVS Health (CVS) PT Lowered to $77 at BofA Securities

May 2, 2024 5:38 AM EDT

BofA Securities analyst Michael Cherny lowered the price target on CVS Health (NYSE: CVS) to $77.00 (from $95.00) while maintaining a Buy rating.

The analyst comments "Shares of CVS currently trade at 8x earnings, implying investors have substantial doubt the company can... More